Solventum Is Maintained at Sell by Goldman Sachs
Solventum Is Maintained at Sell by Goldman
Goldman Sachs Adjusts Price Target on Solventum to $48 From $54
10:04 AM EDT, 07/10/2024 (MT Newswires) -- Goldman Sachs Adjusts Price Target on Solventum to $48 From $54Price: 47.92, Change: -0.10, Percent Change: -0.21
3m's CFO resigned after leadership changes and the separation of the medical care business.
Chemical giant 3m (MMM.US) announced on Wednesday that chief financial officer Monish Patolawala has resigned to "seek other opportunities".
7 Stocks for the Second Half of 2024 That Aren't Nvidia or Other Tech Giants
It is always a good idea to look for stocks that are set up for outperformance in the near future.
7 Stocks Poised for a Strong Second Half. And They Aren't Tech Giants.
It is always a good idea to look for stocks that are set up for outperformance in the near future.
Express News | Watching MediWound; Traders Circulate Solventum Interested In Buying The Company For $34 Per Share
MediWound Jumps Amid Report of $34 a Share Takeover Offer From Solventum
U.S. News & World Report Expands Use of Solventum's Ambulatory Potentially Preventable Complications Grouping Software for Use in Its 2024-2025 Best Hospitals Rankings
ST. PAUL, Minn., July 2, 2024 /PRNewswire/ -- Solventum today announced that U.S. News & World Report is expanding its use of Solventum's 3M Ambulatory Potentially Preventable Complications (AM-PPCs)
The New York Stock Exchange Leads Industry in Global IPO Proceeds for the First Half of 2024
NYSE issuers raise $12 billion as IPO activity builds momentum Welcomes 7 of the 10 largest U.S. transactions The Big Board continues to drive exchange transfers The New York Stock Exchange, part of
Insulet Tops S&P 500 Growth Chart for Q2 as It Gains Market Share in the Diabetes Space
Retail Investors Who Have a Significant Stake Must Be Disappointed Along With Institutions After Solventum Corporation's (NYSE:SOLV) Market Cap Dropped by US$358m
Key Insights The considerable ownership by retail investors in Solventum indicates that they collectively have a greater say in management and business strategy The top 25 shareholders own 41% of th
Should You Be Excited About Solventum Corporation's (NYSE:SOLV) 33% Return On Equity?
Solventum Is Maintained at Neutral by B of A Securities
Solventum Is Maintained at Neutral by B of A Securities
B of A Securities Maintains Neutral on Solventum, Lowers Price Target to $60
B of A Securities analyst Travis Steed maintains Solventum (NYSE:SOLV) with a Neutral and lowers the price target from $70 to $60.
Bottom 10 Performing S&P 500 Names as H1 Looks to Close Out This Week
BofA Securities Maintains Solventum(SOLV.US) With Hold Rating, Cuts Target Price to $60
BofA Securities analyst Travis Steed maintains $Solventum(SOLV.US)$ with a hold rating, and adjusts the target price from $70 to $60.According to TipRanks data, the analyst has a success rate of 60.6%
Express News | Solventum Corp : BofA Global Research Cuts Price Objective to $60 From $70
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scan
Solventum Introduces Denials Prevention Solution, an AI-powered Tool, Empowering Health Systems to Help Reduce Write-offs and Improve Top Line Revenue
ST. PAUL, Minn., June 24, 2024 /PRNewswire/ -- Solventum (NYSE: SOLV), [formerly 3M Health Care] today announced a new artificial intelligence (AI)-driven payment integrity and revenue cycle solution
Argus Research Initiates Solventum(SOLV.US) With Hold Rating
Argus Research analyst David Toung initiates coverage on $Solventum(SOLV.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 63.1% and a total average return of 9.4%